Purpose: A pretherapy 124 I-metaiodobenzylguanidine ͑MIBG͒ positron emission tomography ͑PET͒/computed tomography ͑CT͒ provides a potential method to estimate radiation dose to normal organs, as well as tumors prior to 131 I-MIBG treatment of neuroblastoma or pheochromocytoma. The aim of this work was to estimate human-equivalent internal radiation dose of 124 I-MIBG using PET/CT data in a murine xenograft model. Methods: Athymic mice subcutaneously implanted with NB1691 cells that express high levels of human norepinephrine transporter ͑n=4͒ were imaged using small animal microPET/CT over 96 h ͑approximate imaging time points: 0.5, 2, 24, 52, and 96 h͒ after intravenous administration of 3.07-4.84 MBq of I-MIBG to a detectable level. All four animals were considered as control and organ radiation dosimetry was performed. Volumes of interest were drawn on the coregistered CT images for thyroid, heart, lung, liver, kidney, and bladder, and transferred to PET images to obtain pharmacokinetic data. Based on tabulated organ mass distributions for both mice and adult male human, preclinical pharmacokinetic data were extrapolated to their human-equivalent values. Radiation dose estimations for different age groups were performed using the OLINDA|EXM from ICRP 103 were estimated as follows: Adult female: 0.34, 15-yr-old: 0.39 mSv/MBq, 10-yrold: 0.58 mSv/MBq, 5-yr-old: 1.03 mSv/MBq, 1-yr-old: 1.92 mSv/MBq, and newborn: 3.75 mSv/ MBq. For comparison, the reported effective dose equivalent of 124 I-NaI for adult male ͑25% thyroid uptake, MIRD Dose Estimate Report No. 5͒ was 6.5 mSv/MBq. Conclusions: The authors estimated human-equivalent internal radiation dose of 124 I-MIBG using preclinical imaging data. As a reference, the effective dose estimation showed that 124 I-MIBG would deliver less radiation dose than 124 I-NaI, a radiotracer already being used in patients with thyroid cancer.
I. INTRODUCTION
Iodine-124 is an emerging radionuclide for imaging because iodination techniques are common in developing new tracers for noninvasive nuclear molecular imaging.
1,2 Unlike 123 I which is an excellent radioiodine for imaging using a single photon emission computed tomography, 124 I can be imaged using positron emission tomography ͑PET͒ for more accurate quantification of tracer distribution. In addition, when combined with 131 I therapy such as 131 I-NaI for thyroid cancer or 131 I-metaiodobenzylguanidine ͑MIBG͒ for neuroblastoma or pheochromocytoma, 124 I PET imaging currently is the best modality for pretherapy dosimetry because of its favorable characteristics such as whole-body tomographic capability from PET and a similar half-life ͑4. I can be also used as an imaging agent; however, as an imaging agent, 131 I is not an ideal radiolabel because the gamma emission from 131 I ͑photopeak of 364 keV͒ is not efficiently collected by a typical gamma camera with high-energy collimators and 3/8 in. NaI͑Tl͒ crystal. 3 Roughly 50% or more of photons from 131 I escape the scintillation crystal and the collimators, even if they are designed for high-energy radionuclides such as 131 I, causing high fractions of collimator septa penetration and scatters that greatly degrade image quality of 131 I scans. 3, 4 For these reasons, 124 I-NaI imaging and dosimetry for 131 I-NaI treatment of thyroid cancer has been studied in recent years. [5] [6] [7] [8] [9] [10] [11] [12] [13] There are also other 124 I-labeled radiotracers that have been studied for other types of diseases. [14] [15] [16] [17] [18] However, 124 I-MIBG has not been systematically studied in human subjects. Although there was a report of using 124 I-MIBG in a limited number of human adult subjects ͑n=2͒ with neural crest tumors 19 and animals, 20 children with neuroblastoma or patients with pheochromocytoma were never studied using 124 I-MIBG. A more efficiently labeled form of MIBG ͑no-carrier-added͒ is currently in clinical trials ͑Ultratrace, Molecular Insight Pharmaceuticals, Cambridge, MA͒. This technology allows more activity to be administered with less of the chemical MIBG and ensures that every molecule taken up by the human norepinephrine transporter ͑hNET͒ will carry a radioactive iodine molecule.
As 131   I-MIBG therapy becomes more common and of  proven  efficacy  for  neuroblastoma  and  pheochromocytoma, 21-23 124 I-MIBG pretherapy imaging and dosimetry in these patients will improve efficacy and safety with individualized adjustment of activity administered. As a first step, we performed preclinical imaging with no-carrieradded 124 I-MIBG using animal models in order to assess expected radiation exposures to human subjects. Data extrapolation and radiation dose estimations for models of different age groups are presented. The data presented in this report will be critical components for the Food and Drug Administration ͑FDA͒'s Investigational New Drug application approval.
II. METHODS AND MATERIALS

II.A.
I-MIBG and Animal Models
We have labeled 124 I ͑purchased from IBA Molecular, Louvain-la-Neuve, Belgium͒ with MIBG synthesized from precursors provided by Molecular Insight Pharmaceuticals ͑Cambridge, MA͒. [24] [25] [26] [27] [28] From the reversed phase high performance liquid chromatography spectral analysis, we observed radiochemical purity of Ͼ99%. For thyroid blocking, 0.374 mg/ 100 L of aqueous solution of sodium iodide was administered intravenously to four athymic mice ͑weighing approximately 25 g each͒. The mice were implanted with NB1691 cells that express hNET. We originally intended to investigate the tumor uptake of 124 I-MIBG in these animals. However, the subcutaneous xenograft tumors in these animal models did not accumulate 124 I-MIBG to a detectable level, possibly due to the difference in tumor microenvironments between native tumors and xenograft tumors. Thus, all four mice were considered as normal control subjects, and radiation dosimetry studies followed.
II.B. Small animal PET/CT
A total of 3.07-4.84 MBq of 124 I-MIBG was administered to four mice via tail vein. Small animal PET combined with computed tomography ͑microPET/CT͒ was performed immediately after 124 I-MIBG administration. We used a dedicated PET docked with multimodality CT ͑Inveon, Siemens Healthcare, Malvern, PA͒ for all of our preclinical imaging studies. Each animal was followed for over 96 h by imaging five time points ͑0.5, 2, 24, 52, and 96 h͒. Mice were under anesthesia using isoflurane at 2% concentration.
In order to obtain reasonable image qualities, we applied two PET data acquisition durations. At 0.5, 2, 24, and 52 h reference time points, the data were acquired over 3600 s, and at 96 h, 5400 s. For the 0.5 h reference time point, we used a dynamic acquisition technique to capture early pharmacokinetics of the tracer immediately after the tracer administration. Thus, the actual acquisition time was from 0 to 1 h continuously, making the midtime point as reference at 0.5 h. The durations for the dynamic acquisition were 10 ϫ 10, 5 ϫ 40, 1 ϫ 300, and 5 ϫ 600 s. The 2 h data were also divided into two 1800 s frames.
PET data acquired using a 250-650 keV energy window were reconstructed to a 128ϫ 128ϫ 159 matrix with a voxel size of 0.776 383ϫ 0.776 383ϫ 0.796 mm 3 using the 2D-ordered subsets expectation maximization reconstruction algorithm. The CT images were reconstructed into a 512 ϫ 512ϫ 672 matrix with an isotropic voxel size of 0.190 684ϫ 0.190 684ϫ 0.190 684 mm 3 using a Feldkamp CT reconstruction algorithm modified for x-ray cone beam. The reconstruction algorithms for both PET and CT were provided by the scanner manufacturer. The parameters for microCT were 120 rotation steps over 220°, continuous acquisition, 80 kVp tube voltage, 500 A tube current, and 175 ms exposure.
Image display and analysis were performed using the AMIDE software package. 29 Volumes of interest ͑VOIs͒ were drawn on the coregistered CT images for thyroid, heart, lung, liver, kidney, and bladder, and transferred to PET images to obtain the pharmacokinetic data. Once transferred to PET images, VOIs were adjusted to include apparent partial volume spill-outs for organ uptake calculation. VOIs of the thyroid were drawn with the reference to thyroid 124 I-MIBG PET images because the size of the thyroid was anatomically too small to be localized on CT.
The animal organ % of injected activity ͑%IA͒ data were converted to those for a human using the percent kilogram per gram method of Kirschner et al. 30 The calculated percent injected activity per gram of organ ͑%IA/g͒ for the organs in mice was extrapolated to uptake in organs of a 73.7 kg male adult.
In this method, the human %IA/organ is given as in
The calculated %IA/organ in the human organs was fitted with exponential biokinetic functions and integrated to obtain the number of disintegrations for source organs using the OLINDA|EXM ͑version 1.1͒ software. 32 The same software was used to estimate the effective dose in different age groups. The extracted organ masses and fractions for our radiation dose estimations between mouse and adult male are shown in 
II.C. Dosimetric calculations
OLINDA|EXM software output is the radiation dose per unit of administered activity ͑mSv/MBq͒ in each organ and the total body, as well as effective dose ͑ED͒ and effective dose equivalent. 32, 35 Inputs to OLINDA|EXM are either residence times themselves ͑uCi h/uCi, Bq h/Bq͒ or %IA/organ from which residence times are computed via exponential curve fits. The OLINDA phantoms are adjusted accordingly for different age groups from newborns to human adults. The timeactivity-curves, expressed as percent injected activity per weight of tissue or percent injected activity of tissue ͑%IA/ organ͒, were generated for the organs of interest. Effective dose was estimated for different age groups using the tissue weighting factors defined in the International Commission on Radiological Protection ͑ICRP͒ Publication 103 ͑Ref. 36͒ as well as the values in the ICRP Publication 60. 37 The current version of OLINDA|EXM ͑version 1.1͒ uses the ICRP Publication 60 tissue weighting factors. patterns. High uptake is found in the heart and bladder before the 2 h time point and thyroid uptake is heightened after the 24 h time point. Uptake in liver, kidneys, and lungs decreased continuously over time; however, the percent liver and lung uptake remained relatively high when compared to uptake in other organs even at the 96 h time point mostly due to their large fractions of organ masses. Table II lists the mean %IA/g values in each reported organ of mice. The %IA/g values were calculated by the fractions of activity in each organ ͑%IA͒ divided by organ masses in g ͑e.g., 0.12 g for heart in Table I͒ . Figure 2 illustrates extrapolated human-equivalent percent injected activity ͑%IA/organ͒ data in heart, thyroid, bladder, kidney, liver, and lung. The values shown in Fig. 2 are averaged across all four mice. The %IA/organ values show the expected patterns of pharmacokinetics. Since the thyroid was blocked from 124 I-MIBG by sodium iodide, the uptake in the thyroid was minimized. This process mimics the clinical situation in which patients are given potassium iodide ͑KI͒ as a thyroid-blocking agent.
III. RESULTS
The estimated equivalent dose to the organs and total body, and effective dose, for the reference adult male are summarized in Table III . The mean effective dose to the adult male was estimated to be 0.25 mSv/MBq. The highest mean equivalent dose was in the thyroid, at 2.343 mSv/MBq. Calculated effective doses for the different age groups are shown in Table IV . Effective dose values were higher in female than in male and are higher in the younger subjects than in the older subjects as expected.
IV. DISCUSSION
We have performed internal radiation dosimetry of 124 I-MIBG using microPET/CT in mice for normal organs with extrapolation to human-equivalent radiation dose values. Our results show that 124 I-MIBG PET is a feasible imaging modality for pretherapy dosimetry and the future possibility of its use for the prediction of tumor dose as well. The tissue weight factors extrapolation method ͓Eq. ͑1͔͒ from mice to humans was based on preclinical imaging data. Therefore, the results are estimates of human absorbed dose since this method has uncertainties associated with extrapo- 38 In our study, we also compared the effective dose estimates of 124 I-MIBG to effective doses reported for commonly known radiotracers ͑Table V͒. 39 The most significant finding from this comparison was that the estimated effective dose value of 124 I-MIBG was nearly ten times smaller than that of 124 I-NaI. Such discovery is important because 124 I-NaI is already used clinically at selected research centers. 6, 7, 9, 10, 40 The difference in effective dose values is primarily due to the thyroid blocking, which is performed for I-MIBG ͑11.0/0.21͒. The significant difference in effective doses between NaI and MIBG compounds primarily results from the different patterns of the two radiotracers. While the iodide anion will be taken up in the thyroid, the iodinated MIBG is specifically taken up by sympathetically innervated tissue ͑such as salivary gland͒ or tissue with the organic cation transporter ͑such as liver͒. 41 The 0.25 mSv/MBq radiation dose estimated for I-MIBG is administered, the radiation exposure is estimated at 19.1 mSv, which is already approximately two thirds of effective dose from 555 MBq ͑15 mCi͒ administration of 18 F-flurodeoxyglucose ͑FDG͒ for adult male, 33.3 mSv using the tabulated values listed in Table V . An 18.5 MBq administration may appear to be an insufficient amount of activity to achieve acceptable quality PET images. However, the current PET technologies feature improved sensitivity over previous generations due to increased fields of view, 3-D acquisition. The possibility of allowing relatively long acquisition time per bed, particularly for small children without a requirement for increasing the total acquisition time, will result in accurate data for dosimetric calculations.
Several issues limited the accuracy of the dose calculation method used. In order to estimate the radiation dose using small animal data with high accuracy, we need to pay careful attention to a few specific points. One limitation of this work is the broad range of mouse organ masses from different animals. The underestimation of radiation dose in small organs can be caused by the limited spatial resolution of the microPET scanner when imaging 124 I-labeled radiotracers. However, the estimates of average whole-body dose generally are not significantly affected by partial volume errors. 42 Identifying accurate boundaries of organs is another practical difficulty. In addition, the radiation dose estimate might change depending on how many time points were used to acquire the data, which generally affects the quality of curvefitting procedures using biokinetic time-activity-curves.
We also considered the radiotracer excretion model in our radiation dosimetry based on the total activity changes in the whole body of mice over time. For all imaging time points, the entire body of mice was included in the PET/CT field of view for this calculation. Radiation dose estimates including our excretion model were compared against the published 131 I-MIBG ͑no-carrier-added͒ pharmacokinetic and dosimetry data in humans. 43 Although technologies of estimating the radiation dose are quite different ͑microPET data extrapolation from mouse to human versus two-view anteriorposterior scintigraphy, which lacks robust quantitative measurements of radiotracer distribution͒, our preclinical 124 I-MIBG data were able to predict reasonably precise radiation dose estimates for 131 I-MIBG in humans within 15% of ED difference ͑0.34 mSv/MBq using 
V. CONCLUSION
Radiation absorbed dose estimation for internally administered radiopharmaceuticals using preclinical models is critical when translating a new radiopharmaceutical or a new indication using an existing radiopharmaceutical into clinical trials. The dose estimates for 124 I-MIBG using small animal models in our report showed that 124 I-MIBG would deliver a significantly smaller radiation dose than 124 I-NaI, a radiotracer already being used in human subjects. Our data support the safety of using 124 I-MIBG in humans as long as a relatively small amount of radioactivity is used. For example, the range of 0.5-1 mCi administration would result in effective dose estimates of 19.1-38.1 mSv in the 5-yr-old model. Also, as our results showed, for very young pediatric patients, particularly under 5 years old ͑effective dose estimates over 1 mSv/MBq͒, 124 I-MIBG imaging should be used judiciously and mainly in conjunction with a planned 131 I-MIBG therapy dose, which would then make the pretherapy imaging dose negligible by comparison. 
